Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Flonoltinib maleate vs ruxolitinib in intermediate/high‑risk myelofibrosis
ChiCTR2500115640Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Transfusion
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of flonoltinib in myelofibrosis (MF) (3 arms), sponsored by Institute of Hematology and Blood Transfusion. Primary endpoint: Proportion of subjects with ≥35% reduction in spleen volume vs baseline at Week 24 (IRC assessed). Started Dec 2025; status: completed.
02
Drugs
flonoltinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on ChiCTR2500115640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115640.